Neoadjuvant on the gastroenteropancreatic neuroendocrine tumors: A Systematic Review and Meta-analysis

Hongyang Chen, Zhu Chun-xian, Xingkang He, Wenjie Dong, Leimin SunResearch 2021 · DOI

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare malignancies where surgical resection is the primary curative treatment. However, high recurrence rates necessitate more effective strategies. This systematic review and meta-analysis evaluates the efficacy and safety of neoadjuvant therapy—treatment administered prior to surgery—in patients with GEP-NETs. Analyzing data from eight studies involving 457 patients, the results demonstrate that neoadjuvant therapy significantly improves overall survival (OS) and progression-free survival (PFS) without increasing postoperative complications.

Introduction

GEP-NETs represent a heterogeneous group of tumors arising from the digestive tract's endocrine system. While surgery is the gold standard for treatment, the risk of recurrence remains a significant challenge. In other gastrointestinal cancers, neoadjuvant therapy is used to downstage tumors and improve surgical outcomes. Due to the rarity of GEP-NETs, the clinical value of this approach has remained unclear. This study synthesizes current evidence to determine if neoadjuvant therapy offers a survival advantage for these patients.

Methods

A comprehensive search was conducted across PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, ClinicalTrials.gov, and China National Knowledge for studies published through June 30, 2020. The meta-analysis followed PRISMA and MOOSE guidelines.

  • Data Extraction: For studies lacking explicit Hazard Ratios (HR), data points were extracted from Kaplan-Meier curves using Engauge Digitizer software.
  • Statistical Analysis: Pooled HRs for OS and PFS were calculated using fixed-effects and random-effects models.
  • Quality Assessment: The Newcastle-Ottawa scale was employed to ensure the inclusion of moderate-to-high quality observational studies.

Results

The final analysis included eight retrospective studies covering 457 patients. Neoadjuvant interventions primarily consisted of platinum-based chemotherapy, Peptide Receptor Radionuclide Therapy (PRRT), and chemoradiotherapy.

Survival Outcomes

The neoadjuvant therapy group showed a significant improvement in survival:

  • Overall Survival: The pooled HR was 0.52 (95% CI: 0.41–0.66; P = 0.008), representing a 48% reduction in the risk of death.
  • 5-Year OS: 65.25% in the neoadjuvant group vs. 46.79% in the surgery-only group (P < 0.001).
  • Progression-Free Survival: 5-year PFS was significantly higher in the neoadjuvant group (30.64% vs. 14.46%, P = 0.04).
  • Short-term Survival: 1-year OS was also improved (93.42% vs. 82.48%).

Pathological and Safety Findings

  • Tumor Downsizing: Neoadjuvant therapy led to significantly smaller tumors at the time of surgery (mean 4.4 cm vs. 5.7 cm).
  • Lymph Node Status: A higher proportion of patients achieved N0 status (no lymph node involvement) following neoadjuvant treatment (68.1% vs. 49.09%).
  • Safety: There was no significant difference in postoperative complication rates between the groups (30% vs. 29.4%, P = 0.52), indicating that neoadjuvant therapy does not compromise surgical safety.

Discussion

The findings suggest that neoadjuvant therapy effectively "downstages" GEP-NETs, leading to smaller tumor sizes and improved lymph node status, which likely contributes to the observed survival benefits. Even in cases with liver metastases, a survival benefit was maintained (HR 0.62).

Conclusion and Future Directions

Neoadjuvant therapy provides a significant survival advantage for patients with operable GEP-NETs without increasing surgical risks. However, the reliance on retrospective data and the relatively small sample size are limitations. Future large-scale, multicenter randomized clinical trials are necessary to standardize treatment protocols and identify which patient subgroups benefit most from this approach.

Summary updated

Abstract

Abstract Background Clinical value of neoadjuvant therapy has been proven in many malignancies. With a low prevalence of neuroendocrine tumors, the survival benefits of neoadjuvant therapy in gastroenteropancreatic neuroendocrine tumors (GEP-NET) are still unclear based on the up-to-date literature. Aim To assess the effectiveness of neoadjuvant therapy on GEP-NET. Methods Articles were searched electrically on PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, ClinicalTrials.gov and China National Knowledge from inception to 30th June 2020. The survival benefit was assessed by Hard ratio (HR) for overall survival (OS). Median OS, progression-free survival (PFS) and complications were also compared. Results This meta-analysis eventually included eight studies with a total of 457 patients. The overall survival of GEP-NET patients in the neoadjuvant therapy group was improved significantly (HR = 0.52; 95% confidence interval, 0.41–0.66; P = 0.008). There was a dramatic improvement in OS (5-year OS 65.25% vs. 46.79% P &lt; 0.001) and PFS (5-year PFS 30.64% VS 14.46%, P = 0.04) in the neoadjuvant therapy group. There was no difference in the postoperative complications among the two groups ( P = 0.52). Conclusions Patients with operable GEP-NETs can achieve a significant improvement in overall survival with neoadjuvant therapy. Further large randomized clinical trials are expected to confirm the results.
BibTeX
@inproceedings{chen2021neoadjuvant,
  author = {Hongyang Chen and Zhu Chun-xian and Xingkang He and Wenjie Dong and Leimin Sun},
  title = {{Neoadjuvant on the gastroenteropancreatic neuroendocrine tumors: A Systematic Review and Meta-analysis}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-208725/v1},
}
Figure